[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11202001604UA - Anti-ctla4 antibodies and uses thereof - Google Patents

Anti-ctla4 antibodies and uses thereof

Info

Publication number
SG11202001604UA
SG11202001604UA SG11202001604UA SG11202001604UA SG11202001604UA SG 11202001604U A SG11202001604U A SG 11202001604UA SG 11202001604U A SG11202001604U A SG 11202001604UA SG 11202001604U A SG11202001604U A SG 11202001604UA SG 11202001604U A SG11202001604U A SG 11202001604UA
Authority
SG
Singapore
Prior art keywords
ctla4 antibodies
ctla4
antibodies
Prior art date
Application number
SG11202001604UA
Other languages
English (en)
Inventor
Yi Yang
Yanan Guo
Xiaodong Cheng
Yunyun Chen
Jingshu Xie
Chunyan Dong
Fang Yang
Chengyuan Lu
Yuelei Shen
Jian Ni
Original Assignee
Eucure Beijing Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eucure Beijing Biopharma Co Ltd filed Critical Eucure Beijing Biopharma Co Ltd
Publication of SG11202001604UA publication Critical patent/SG11202001604UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202001604UA 2017-09-21 2017-09-21 Anti-ctla4 antibodies and uses thereof SG11202001604UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/102816 WO2019056281A1 (fr) 2017-09-21 2017-09-21 Anticorps anti-ctla4 et utilisations associées

Publications (1)

Publication Number Publication Date
SG11202001604UA true SG11202001604UA (en) 2020-04-29

Family

ID=65810881

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001604UA SG11202001604UA (en) 2017-09-21 2017-09-21 Anti-ctla4 antibodies and uses thereof

Country Status (12)

Country Link
US (3) US11034764B2 (fr)
EP (1) EP3684812A4 (fr)
JP (2) JP7155270B2 (fr)
KR (1) KR102543719B1 (fr)
CN (1) CN111406069B (fr)
AU (1) AU2017432728B2 (fr)
BR (1) BR112020005496A2 (fr)
CA (1) CA3073984A1 (fr)
IL (2) IL272993A (fr)
MX (1) MX2020003132A (fr)
SG (1) SG11202001604UA (fr)
WO (1) WO2019056281A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019006340A (es) 2016-12-07 2019-11-07 Agenus Inc Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
WO2019056281A1 (fr) 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anticorps anti-ctla4 et utilisations associées
KR20240023192A (ko) 2017-11-24 2024-02-20 유큐(베이징) 바이오파마 코., 엘티디 항―ｏｘ４０ 항체 및 그의 용도
AU2019407814A1 (en) 2018-12-21 2021-07-22 Boehringer Ingelheim International Gmbh Bifunctional anti-PD-1/IL-7 molecule
WO2020165374A1 (fr) 2019-02-14 2020-08-20 Ose Immunotherapeutics Molécule bifonctionnelle comprenant il-15ra
WO2021098851A1 (fr) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anticorps bispécifiques anti-ctla4/ox40 et leurs utilisations
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
CN111789954B (zh) * 2020-09-08 2020-12-15 北京百奥赛图基因生物技术有限公司 延缓衰老的方法和药物
WO2022112198A1 (fr) 2020-11-24 2022-06-02 Worldwide Innovative Network Procédé de sélection des thérapies optimales par points de contrôle immunitaire
KR20220112208A (ko) * 2021-02-03 2022-08-10 주식회사 유틸렉스 항 ctla-4 항체 및 이의 용도
WO2022214653A1 (fr) 2021-04-09 2022-10-13 Ose Immunotherapeutics Nouvel échafaudage pour molécules bifonctionnelles présentant des propriétés améliorées
EP4320156A1 (fr) 2021-04-09 2024-02-14 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
CN112921005B (zh) * 2021-04-14 2023-07-07 中国农业科学院兰州兽医研究所 一株杂交瘤细胞株及其产生的犬细小病毒vp2蛋白单克隆抗体和应用
CN113754770B (zh) * 2021-10-21 2023-11-03 江苏诺迈博生物医药科技有限公司 一种特异性结合人ctla4的抗体及包含其的药物和试剂盒
US20230404642A1 (en) * 2022-06-01 2023-12-21 Syncromune, Inc. Method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients
WO2024003360A1 (fr) 2022-07-01 2024-01-04 Institut Curie Biomarqueurs et leurs utilisations pour le traitement du neuroblastome
WO2024028386A1 (fr) 2022-08-02 2024-02-08 Ose Immunotherapeutics Molécule multifonctionnelle dirigée contre cd28
WO2024049203A1 (fr) * 2022-09-02 2024-03-07 주식회사 시클리드 Anticorps monoclonal anti-ctla-4 et utilisation associée
WO2024088424A1 (fr) * 2022-10-28 2024-05-02 嘉和生物药业有限公司 Nouvel anticorps anti-ctla4
WO2024200823A1 (fr) 2023-03-30 2024-10-03 Ose Immunotherapeutics Nanoparticule à base de lipide ciblant des cellules immunitaires activées pour l'expression d'une molécule d'amélioration de cellule immunitaire et son utilisation
WO2024200820A1 (fr) 2023-03-30 2024-10-03 Ose Immunotherapeutics Procédé de synthèse de nanoparticule lipidique ciblée et ses utilisations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
WO1989001973A2 (fr) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
WO1991002805A2 (fr) 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
HUP0300369A2 (hu) 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
CN1802388B (zh) 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法
CN1964739A (zh) 2004-03-26 2007-05-16 辉瑞产品公司 抗ctla－4抗体的用途
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009111655A (ja) 2007-10-30 2009-05-21 Alaxala Networks Corp ネットワーク管理システム
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
SI3303394T1 (sl) * 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
WO2017062797A1 (fr) * 2015-10-07 2017-04-13 The University Of North Carolina At Chapel Hill Méthodes de traitement de tumeurs
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
WO2019056281A1 (fr) 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anticorps anti-ctla4 et utilisations associées
WO2021098851A1 (fr) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anticorps bispécifiques anti-ctla4/ox40 et leurs utilisations
JP2023524669A (ja) * 2020-04-26 2023-06-13 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 改変免疫グロブリン

Also Published As

Publication number Publication date
KR20200054220A (ko) 2020-05-19
US20200291117A1 (en) 2020-09-17
US20210188981A1 (en) 2021-06-24
US12054547B2 (en) 2024-08-06
CN111406069B (zh) 2022-12-30
BR112020005496A2 (pt) 2020-09-29
JP2022179611A (ja) 2022-12-02
EP3684812A4 (fr) 2021-09-08
IL272993A (en) 2020-04-30
CA3073984A1 (fr) 2019-03-28
JP7155270B2 (ja) 2022-10-18
CN111406069A (zh) 2020-07-10
JP2021503294A (ja) 2021-02-12
WO2019056281A1 (fr) 2019-03-28
RU2020111428A3 (fr) 2021-10-21
AU2017432728A1 (en) 2020-02-27
US20240343806A1 (en) 2024-10-17
AU2017432728B2 (en) 2024-11-07
US11034764B2 (en) 2021-06-15
KR102543719B1 (ko) 2023-06-16
EP3684812A1 (fr) 2020-07-29
IL304144A (en) 2023-09-01
MX2020003132A (es) 2020-07-28
RU2020111428A (ru) 2021-10-21

Similar Documents

Publication Publication Date Title
IL304144A (en) Anti- ctla4 antibodies and uses thereof
IL290842A (en) Anti-cd73 antibodies and uses thereof
ZA202102905B (en) Anti-galectin-9 antibodies and uses thereof
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and their uses
IL276950A (en) Anti-CD73 antibodies and uses thereof
ZA202000113B (en) Anti-ctla-4 antibodies and uses thereof
IL282968A (en) Anti-NKG2A antibodies and their use
IL269134A (en) Antibodies against PAR2 and their use
IL275826A (en) Anti-mct1 antibodies and their uses
IL272476A (en) Anti-Apelin antibodies and their uses
IL281297A (en) Anti-NPR1 antibodies and uses thereof
IL273157A (en) Antibodies specific to AXL and their uses
IL271398A (en) Anti-l1-cam antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL277330A (en) Anti-IL-27 antibodies and uses thereof
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
GB201712032D0 (en) Antibodies and uses thereof
IL283926A (en) Antibodies against alpha-synuclein and their uses
IL283890A (en) Anti-periostin antibodies and their uses